{"id":"NCT03760068","sponsor":"Mylan Inc.","briefTitle":"Mylan Insulin Aspart Study","officialTitle":"A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D With NovoLog® in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-07","primaryCompletion":"2019-12-28","completion":"2020-01-17","firstPosted":"2018-11-30","resultsPosted":"2021-01-27","lastUpdate":"2022-02-25"},"enrollment":478,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"MYL-1601D Product","otherNames":[]},{"type":"DRUG","name":"FlexPen NovoLog®","otherNames":[]}],"arms":[{"label":"MYL-1601D Product (100 U/mL)","type":"ACTIVE_COMPARATOR"},{"label":"FlexPen NovoLog® (100 U/mL)","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this phase III trial is to demonstrate the equivalence in the safety and efficacy profile between MYL-1601D and NovoLog® in patients with T1DM.","primaryOutcome":{"measure":"Treatment Emergent Antibody Response (TEAR)","timeFrame":"Baseline to week 24","effectByArm":[{"arm":"MYL-1601D Product (100 U/mL)","deltaMin":59,"sd":null},{"arm":"FlexPen NovoLog® (100 U/mL)","deltaMin":67,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":158,"countries":["United States"]},"refs":{"pmids":["36114990"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":238},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Urinary Tract Infection","Headache","Hypertension"]}}